SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors

Part of paid clinical trials in Newport Beach, California.

Sponsor
Solve Therapeutics
Study ID
NCT07728942
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SLR-108 — DRUG
    SLR-108 is an antibody-radionuclide conjugate.
  • SLX-1411 — DRUG
    SLX-1411 is a non-radiolabeled antibody.

Study Details

This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.

Key Dates

First listed
Jul 27, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Jan 31, 2028
Completion
Feb 29, 2028

Study Design

Enrollment
70 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Part 1: Cohort 1
    Low total antibody dose, initial radioactivity dose
  • Experimental: Part 1: Cohort 2
    Medium total antibody dose, initial radioactivity dose
  • Experimental: Part 1: Cohort 3
    High total antibody dose, initial radioactivity dose
  • Experimental: Part 2
    TBD total antibody dose, lower TBD radioactivity dose
  • Experimental: Part 3
    TBD total antibody dose, TBD radioactivity dose

Primary Outcome Measure

Optimal antibody protein dose [ Time Frame: Through Day 14 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92663
Hoag Molecular Imaging and Therapy
[email protected]
949-557-0285

Find similar trials in Newport Beach, CA

By research site
Hoag Memorial Hospital Presbyterian· Newport Beach, CA

Related Studies